Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial

Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now shows a new Revision: v3.4.2, and the previous funding-status notice and Revision: v3.4.1 have been removed.
    Difference
    0.2%
    Check dated 2026-02-11T06:17:01.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The history shows a site-wide funding notice and a new page revision to v3.4.1, replacing v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-04T04:57:12.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a Show glossary toggle and clarified color-coded change indicators (green for additions, red for deletions) on the history page. Updated the revision label to v3.4.0, replacing the previous v3.3.4.
    Difference
    0.3%
    Check dated 2026-01-28T03:18:03.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    New site revision v3.3.4 appears in the history, indicating a minor update; no study data or page content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:34:39.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added Outcome Measures (Results), References, and Study Status, and updated revision to v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.2%
    Check dated 2025-12-23T09:24:42.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    The record history adds a 'Results Posted' entry and updates multiple results-related sections (Outcome Measures, Adverse Events, Baseline Characteristics, Participant Flow, IPD Sharing, Study Description/Design) with a new version dated 2025-11-14, replacing the previous 'Results Submitted' entry.
    Difference
    0.6%
    Check dated 2025-12-08T23:56:04.000Z thumbnail image

Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.